Evidence map›Paper›PMID 30318519›Full record

ArticleBritish journal of cancer2018

Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells.

Souvik Chakraborty, Chang Jiang, David Gau, Michael Oddo, Zhijie Ding, Laura Vollmer, Marion Joy, William Schiemann, Donna Beer Stolz, Andreas Vogt and 2 more

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Autophagy and Cancer Dormancy.Frontiers in oncology · 2021
    Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Souvik ChakrabortyBioengineering, University of Pittsburgh, Pittsburgh, USA.
Chang JiangBioengineering, University of Pittsburgh, Pittsburgh, USA.
David GauBioengineering, University of Pittsburgh, Pittsburgh, USA.
Michael OddoBioengineering, University of Pittsburgh, Pittsburgh, USA.
Zhijie DingBioengineering, University of Pittsburgh, Pittsburgh, USA.
Laura VollmerDrug Discovery Institute, University of Pittsburgh, Pittsburgh, USA.
Marion JoyBioengineering, University of Pittsburgh, Pittsburgh, USA.
William SchiemannCase Western Reserve University, Cleveland, USA.
Donna Beer StolzCell Biology, University of Pittsburgh, Pittsburgh, USA.
Andreas VogtDrug Discovery Institute, University of Pittsburgh, Pittsburgh, USA.
Sujoy GhoshCenter for Computational Biology, Duke-NUS Medical School, Singapore, Singapore.
Partha RoyBioengineering, University of Pittsburgh, Pittsburgh, USA. par19@pitt.edu.
University of Pittsburgh · USDiscovery Institute · USCase Western Reserve University · USDuke-NUS Medical School · SGNSABP Foundation · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
Profilin as a target to suppress Invasive breast cancerR01CA108607 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROY, PARTHA · 2006 to 2017
$2.6M
Training Program in Skin Biology and CancerT32CA175294 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2014 to 2018
$973k
Improving genomic prediction models in breast cancerR21CA108707 · NCI · DUKE UNIVERSITY · PI OLSON, JOHN A · 2004 to 2005
$277k
NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA108607NCI NIH HHS R21 CA108707NCI NIH HHS T32 CA175294
6 · The paper itself

Abstract

backgroundAdhesion-mediated activation of FAK/ERK signalling pathway, enabled by the formation of filopodial protrusions (FLP), has been shown to be an important event for triggering of dormancy-to-proliferation switch and metastatic outgrowth of breast cancer cells (BCC). We studied the role of actin-binding protein profilin1 (Pfn1) in these processes.

methodsQuantitative immunohistochemistry (IHC) of BC tissue microarray (TMA) and survival analyses of curated transcriptome datasets of BC patients were performed to examine Pfn1's association with certain clinicopathological features. FLP formation and single cell outgrowth of BCC were assessed using a 3D matrigel culture that accurately predicts dormant vs metastatic outgrowth phenotypes of BCC in certain microenvironment. Gene expression studies were performed to identify potential biological pathways that are perturbed under Pfn1-depleted condition.

resultsLower Pfn1 expression is correlated with lower nuclear grade of breast tumours and longer relapse-free survival of BC patients. Pfn1 depletion leads to defects in FLP and outgrowth of BCC but without impairing either FAK or ERK activation. Guided by transcriptome analyses, we further showed that Pfn1 depletion is associated with prominent SMAD3 upregulation. Although knockdown and overexpression experiments revealed that SMAD3 has an inhibitory effect on the outgrowth of breast cancer cells, SMAD3 knockdown alone was not sufficient to enhance the outgrowth potential of Pfn1-depleted BCC suggesting that other proliferation-regulatory pathways in conjunction with SMAD3 upregulation may underlie the outgrowth-deficient phenotype of BCC cells upon depletion of Pfn1.

conclusionOverall, these data suggest that Pfn1 may be a novel biomarker for BC recurrence and a possible target to reduce metastatic outgrowth of BCC.

Indexed as

Up-RegulationBreast NeoplasmsCell Culture TechniquesCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansNeoplasm GradingProfilinsPrognosisSignal TransductionSmad3 ProteinSurvival AnalysisTissue Array AnalysisTumor MicroenvironmentPFN1 protein, humanProfilinsSmad3 ProteinSMAD3 protein, human

Identifiers

PMID30318519
PMCPMC6219497
OpenAlexW2897482127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.